Family history of prostate cancer should include second- and third-degree relatives
the ONA take:
According to a new study published in the journal The Prostate, researchers from Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, have found that looking at a man's second- and third-degree relatives may be as significant as looking at his first-degree relatives to determine his risk for developing prostate cancer.
Typically, a physician will ask a patient about family members with prostate cancer, and that patient may indicate whether it is a first-degree relative, but researchers wanted to know if second- and third-degree relatives were equally as important to estimate prostate cancer risk for men based on prostate cancer family history. The researchers analyzed data from the Utah Population Database to estimate cancer risk for more than 7.3 million people based on family history.
Results showed that 10% of patients had three times the risk and 26% had two times the risk compared with men with no first-, second-, or third-degree relatives with prostate cancer.
The researchers plan to further investigate the effect of having both a maternal and paternal family history of prostate cancer, as well as other factors, to better calculate cancer risk.
The team is also investigating family history risk assessments for breast and lung cancers. Knowing a patient's family history, and therefore risk for developing cancer, will better determine which patients should receive further screening.
A man's second- and third-degree relatives may be as significant as looking at his first-degree relatives to determine his risk for developing prostate cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|